A Phase 2 interventional study of Intravenous immunoglobulin and Placebo in Psychosis and Autoimmune Encephalitis, sponsored by University of Cambridge. Active, not recruiting at 10 sites in United Kingdom. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University of Cambridge · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Psychotic Disorders with a site in United Kingdom — 19 open to participants now, 22 under way, 4 of them phase 3. Psychotic Disorders · United Kingdom.
Among the 75 studies in Psychotic Disorders with a site in United Kingdom, this one is the 26th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2017, is one of 2 in phase 2, reaches primary completion later than 9 of the 21 other live ones, and was the 25th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →19 of the 75 studies in Psychotic Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom, Austria, Germany and 6 more countries
Ages 16–40
Lancashire and South Cumbria NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 55–90
University of Manchester · Sites in United Kingdom
Ages 16+
University of Nottingham · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 12 · Phase 4 5
First in 2002; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 59 across the 60 interventional studies, 300 across the 15 observational. Of the 45 that completed or were terminated, 9 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 75 have an industry lead sponsor. The 10 most frequent:
University of Cambridge is the lead sponsor of 116 studies on the registry; 23 are open to participants now.
University of Cambridge has 3 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Psychotic Disorders with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252206University of ManchesterA Case Series of Culturally-adapted CBTp for Black People in the UK | 2026-12 |
| NCT07398365University of EdinburghMedical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients | 2026-12-31 |
| NCT06957808King's College LondonInvestigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia | 2027-01-20 |
| NCT03194815University of CambridgeIVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 | 2027-04-30 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 75 studies in Psychotic Disorders with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomised phase II double-blinded placebo-controlled trial designed to explore the utility of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes (NMDA-receptor or Voltage Gated Potassium Channel).
Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.
Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.
Investigators propose a randomised double-blinded placebo-controlled trial to test the hypothesis that immunotherapy is an effective treatment of antibody-associated psychosis, either first episode of psychosis or relapse following previous remission. Immunotherapy for the trial consists of one cycle of intravenous immunoglobulin (IVIG: 2g/kg over days 1-4) followed by two infusions of 1g rituximab (at day 28-35, and then 14 days after the first infusion). The rationale for this regime is that it combines a rapid-action treatment (IVIG) to induce remission with a longer-action therapy (rituximab) to maintain remission. It is based on a protocol where elimination of circulating antibodies is the treatment goal, namely "desensitisation" of potential transplant patients who have multiple anti-HLA antibodies capable of inducing hyperacute rejection and also being tested in various trials on clinicaltrials.gov (NCT00642655, NCT01178216, and NCT01502267). Blinding is required to minimise placebo responses in a trial based on symptomatology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
Drug: Intravenous immunoglobulin · Drug: Rituximab
One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
Drug: Placebo
This is a blood product containing antibodies from thousands of healthy donors.
Also known as: IVIG, Intratect
This is the control, or sham, treatment
Also known as: Saline solution
Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
Also known as: MabThera
Time to start of symptomatic recovery (symptomatic remission sustained for at least 6 months)
remission defined as Positive and Negative Syndrome Scale (PANSS) score 3 or less on PANSS items P1, P2, P3, N1, N4, N6, G5 and G9 sustained for 6 months
Time frame: up to 18 months
Time to first treatment response (whether sustained or not)
Treatment response defined as score of 3 or less on each of the following PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9.
Time frame: up to 18 months
Relapse rate
Relapse rate is defined as a score 4 or more on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9.
Time frame: 18 months
Number of adverse effects
total number of patient reported adverse effects
Time frame: 18 months
Proportion of patients reaching 20% reduction in PANSS total score
20% reduction in the PANSS total score (all PANNS items included)
Time frame: 12 months
Proportion of patients reaching 30% reduction in PANSS total score
30% reduction in the PANSS total score (all PANNS items included)
Time frame: 12 months
Proportion of patients reaching 40% reduction in PANSS total score
40% reduction in the PANSS total score (all PANNS items included)
Time frame: 12 months
Changes in the Clinical Global Impression Scale in Schizophrenia (CGI-Schizophrenia)
Change in CGI-Schizophrenia scores from baseline to month 12
Time frame: 12 months
Changes in the Young Mania Rating Scale (YMRS)
Change in YMRS total score from baseline to month 12
Time frame: 12 months
Changes in the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS)
Change in ANNSERS total score from baseline to month 12
Time frame: 12 months
Changes in the Brief Assessment of Cognition in Schizophrenia (BACS)
Change in BACS scores from baseline to month 12
Time frame: 12 months
Changes in the Global Assessment of Functioning scale (GAF)
Change in the GAF score from baseline to month 12
Time frame: 12 months
Plan to share: Undecided
Started Nov 2017 (actual). Primary completion is estimated for Apr 2027, 113 months after the start.
Of 28 non-industry phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 53. This study's planned 113 months is above that.
Counting every sponsor, half of 39 studies reached it within 39 months; a quarter within 22 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulins, Intravenous · Rituximab